Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline includes KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
Company profile
Website
CEO
Victor Perlroth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
203326750
Latest filings (excl ownership)
15-12G
Securities registration termination
2 Jan 09
10-Q
2008 Q1
Quarterly report
14 May 08
10QSB
2007 Q3
Quarterly report (small business)
13 Nov 07
10QSB
2007 Q2
Quarterly report (small business)
13 Aug 07
10QSB
2007 Q1
Quarterly report (small business)
11 May 07
10QSB
2006 Q3
Quarterly report (small business)
13 Nov 06
10QSB
2006 Q2
Quarterly report (small business)
14 Aug 06
10QSB
2006 Q1
Quarterly report (small business)
12 May 06
Latest ownership filings
No filings